《新股表現》中國抗體-B(03681.HK)開報7.3元 低上市價3.9%
中國抗體-B(03681.HK)暗盤低開7.9%報7元獲承接,平收7.6元;該股首掛開報7.3元,較上市價7.6元,低3.9%,市場成交2,109萬股。
中國抗體是專門研發、製造及商業化免疫性疾病療法的香港生物製藥公司,主要研製以單克隆抗體為基礎的生物藥。是次上市共發售1.82億股,並已引入雲南白藥(000538.SZ)及瑞捷軟件科技為基石投資者,合共認購約6,192萬股(禁售期6個月);其中10%公開發售獲近12倍超購,人人有份,股份以招股範圍(7.6-9.6元)下限定價,料集資淨額12.86億元,主要用作研發和商業化其核心產品,以及建設蘇州生產基地等。上市聯席保薦人分別為中金公司及東方證券。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.